| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 14 | 2025 | 826 | 1.480 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2025 | 1135 | 1.310 |
Why?
|
| Maximum Tolerated Dose | 17 | 2025 | 158 | 1.070 |
Why?
|
| Central Nervous System Neoplasms | 7 | 2025 | 197 | 1.030 |
Why?
|
| Neoplasms | 17 | 2025 | 2788 | 1.020 |
Why?
|
| Child | 99 | 2025 | 24454 | 0.990 |
Why?
|
| Adolescent | 79 | 2025 | 19329 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1237 | 0.910 |
Why?
|
| Proton Therapy | 6 | 2023 | 123 | 0.860 |
Why?
|
| Child, Preschool | 64 | 2025 | 14050 | 0.840 |
Why?
|
| Female | 117 | 2025 | 66555 | 0.760 |
Why?
|
| Male | 110 | 2025 | 61285 | 0.750 |
Why?
|
| Humans | 162 | 2025 | 124797 | 0.740 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 720 | 0.620 |
Why?
|
| Autism Spectrum Disorder | 6 | 2021 | 393 | 0.600 |
Why?
|
| Young Adult | 36 | 2025 | 8987 | 0.600 |
Why?
|
| Singing | 2 | 2016 | 6 | 0.570 |
Why?
|
| Eosinophilic Esophagitis | 4 | 2021 | 75 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2021 | 848 | 0.550 |
Why?
|
| Parents | 11 | 2025 | 1029 | 0.540 |
Why?
|
| Pyridines | 4 | 2021 | 230 | 0.540 |
Why?
|
| Brain Neoplasms | 6 | 2022 | 1243 | 0.540 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 530 | 0.510 |
Why?
|
| Food Hypersensitivity | 4 | 2021 | 152 | 0.500 |
Why?
|
| Diabetic Ketoacidosis | 4 | 2024 | 160 | 0.490 |
Why?
|
| Peanut Hypersensitivity | 3 | 2022 | 75 | 0.480 |
Why?
|
| Quality of Life | 10 | 2024 | 1948 | 0.460 |
Why?
|
| Asthma | 4 | 2024 | 748 | 0.460 |
Why?
|
| Anesthesiology | 3 | 2022 | 93 | 0.450 |
Why?
|
| Infant | 34 | 2024 | 12483 | 0.450 |
Why?
|
| Heart Arrest | 3 | 2024 | 351 | 0.450 |
Why?
|
| Cyclopentanes | 2 | 2024 | 20 | 0.450 |
Why?
|
| Urinary Catheterization | 2 | 2013 | 81 | 0.450 |
Why?
|
| Cognition | 5 | 2022 | 731 | 0.450 |
Why?
|
| Education, Professional | 1 | 2013 | 10 | 0.440 |
Why?
|
| Liver Diseases | 3 | 2023 | 366 | 0.440 |
Why?
|
| Voice Disorders | 1 | 2013 | 18 | 0.430 |
Why?
|
| Internship and Residency | 5 | 2024 | 1177 | 0.430 |
Why?
|
| Adult | 44 | 2025 | 29472 | 0.430 |
Why?
|
| Neuroblastoma | 4 | 2023 | 519 | 0.420 |
Why?
|
| Pyrazoles | 4 | 2021 | 307 | 0.420 |
Why?
|
| Vocal Cords | 1 | 2013 | 65 | 0.410 |
Why?
|
| Rheumatic Heart Disease | 3 | 2019 | 37 | 0.410 |
Why?
|
| Arachis | 3 | 2022 | 73 | 0.400 |
Why?
|
| Salvage Therapy | 3 | 2019 | 194 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 2424 | 0.390 |
Why?
|
| Sarcoma, Ewing | 3 | 2022 | 116 | 0.380 |
Why?
|
| Pilot Projects | 12 | 2025 | 1402 | 0.380 |
Why?
|
| Truth Disclosure | 3 | 2018 | 103 | 0.380 |
Why?
|
| Acetylcysteine | 2 | 2023 | 72 | 0.370 |
Why?
|
| Resource Allocation | 1 | 2011 | 52 | 0.370 |
Why?
|
| Hemorrhagic Disorders | 2 | 2022 | 17 | 0.370 |
Why?
|
| Occupational Health | 1 | 2011 | 44 | 0.370 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 95 | 0.370 |
Why?
|
| Astronauts | 1 | 2011 | 51 | 0.370 |
Why?
|
| Simulation Training | 3 | 2024 | 139 | 0.360 |
Why?
|
| Health Status Indicators | 1 | 2011 | 121 | 0.360 |
Why?
|
| Pyrimidines | 2 | 2024 | 372 | 0.360 |
Why?
|
| von Willebrand Diseases | 2 | 2022 | 51 | 0.350 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2024 | 316 | 0.350 |
Why?
|
| Health Behavior | 1 | 2013 | 386 | 0.350 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2020 | 46 | 0.350 |
Why?
|
| Retrospective Studies | 32 | 2024 | 16299 | 0.340 |
Why?
|
| Menorrhagia | 2 | 2022 | 74 | 0.340 |
Why?
|
| Spinal Cord Injuries | 1 | 2013 | 311 | 0.340 |
Why?
|
| Rhabdomyosarcoma | 2 | 2023 | 200 | 0.340 |
Why?
|
| Clinical Competence | 8 | 2024 | 997 | 0.330 |
Why?
|
| Space Flight | 1 | 2011 | 117 | 0.330 |
Why?
|
| Sirolimus | 2 | 2024 | 223 | 0.330 |
Why?
|
| Craniospinal Irradiation | 2 | 2021 | 58 | 0.330 |
Why?
|
| Prospective Studies | 16 | 2022 | 6137 | 0.330 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 301 | 0.320 |
Why?
|
| Diabetic Retinopathy | 2 | 2021 | 157 | 0.310 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 42 | 0.310 |
Why?
|
| Anemia, Sickle Cell | 2 | 2024 | 339 | 0.300 |
Why?
|
| Psychometrics | 3 | 2021 | 676 | 0.300 |
Why?
|
| Kidney Failure, Chronic | 4 | 2018 | 880 | 0.300 |
Why?
|
| Follow-Up Studies | 15 | 2024 | 5153 | 0.290 |
Why?
|
| Staphylococcus aureus | 3 | 2020 | 460 | 0.290 |
Why?
|
| Professional Competence | 2 | 2018 | 96 | 0.290 |
Why?
|
| Physician-Patient Relations | 2 | 2024 | 426 | 0.290 |
Why?
|
| Allergens | 4 | 2021 | 252 | 0.290 |
Why?
|
| Hydrocortisone | 3 | 2018 | 219 | 0.280 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 110 | 0.280 |
Why?
|
| Treatment Outcome | 21 | 2025 | 12342 | 0.280 |
Why?
|
| Cystic Fibrosis | 2 | 2023 | 257 | 0.270 |
Why?
|
| Tonsillectomy | 2 | 2021 | 97 | 0.270 |
Why?
|
| Anxiety | 1 | 2013 | 967 | 0.270 |
Why?
|
| Aortic Aneurysm | 3 | 2014 | 235 | 0.270 |
Why?
|
| Self Report | 5 | 2022 | 520 | 0.270 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 873 | 0.260 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2016 | 114 | 0.260 |
Why?
|
| Killer Cells, Natural | 2 | 2019 | 324 | 0.250 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 153 | 0.250 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 1664 | 0.250 |
Why?
|
| Vaccines | 2 | 2021 | 369 | 0.250 |
Why?
|
| Pain, Postoperative | 3 | 2013 | 257 | 0.250 |
Why?
|
| Health Personnel | 3 | 2024 | 505 | 0.250 |
Why?
|
| Curriculum | 6 | 2023 | 723 | 0.250 |
Why?
|
| Telemedicine | 2 | 2022 | 439 | 0.240 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2023 | 78 | 0.240 |
Why?
|
| Hydrazines | 1 | 2025 | 29 | 0.240 |
Why?
|
| Vaccination | 3 | 2021 | 952 | 0.240 |
Why?
|
| Drug Resistant Epilepsy | 2 | 2018 | 208 | 0.240 |
Why?
|
| Immunoglobulin A | 2 | 2024 | 208 | 0.240 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2019 | 314 | 0.240 |
Why?
|
| Time Factors | 14 | 2019 | 6309 | 0.240 |
Why?
|
| Communication | 5 | 2024 | 517 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 154 | 0.230 |
Why?
|
| Biomarkers | 8 | 2024 | 3063 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2019 | 449 | 0.230 |
Why?
|
| Hospitals, Pediatric | 6 | 2019 | 775 | 0.230 |
Why?
|
| Triazoles | 1 | 2025 | 139 | 0.230 |
Why?
|
| Developmental Disabilities | 2 | 2021 | 709 | 0.220 |
Why?
|
| Particulate Matter | 1 | 2024 | 69 | 0.220 |
Why?
|
| Heart-Assist Devices | 3 | 2018 | 1053 | 0.220 |
Why?
|
| Staphylococcal Infections | 3 | 2013 | 558 | 0.220 |
Why?
|
| Peer Group | 1 | 2024 | 119 | 0.220 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 779 | 0.220 |
Why?
|
| Glycine | 2 | 2023 | 167 | 0.220 |
Why?
|
| Blood Glucose | 4 | 2024 | 1142 | 0.220 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 3726 | 0.210 |
Why?
|
| Insulin Infusion Systems | 1 | 2023 | 66 | 0.210 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 872 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 422 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1272 | 0.210 |
Why?
|
| Glutathione | 2 | 2023 | 193 | 0.210 |
Why?
|
| Age Factors | 9 | 2024 | 2817 | 0.210 |
Why?
|
| Phenylbutyrates | 1 | 2023 | 58 | 0.210 |
Why?
|
| Middle Aged | 21 | 2024 | 26717 | 0.210 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 812 | 0.210 |
Why?
|
| Mentors | 1 | 2024 | 143 | 0.210 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2023 | 125 | 0.210 |
Why?
|
| Craniopharyngioma | 1 | 2023 | 33 | 0.210 |
Why?
|
| Texas | 12 | 2021 | 3590 | 0.200 |
Why?
|
| Patient Compliance | 3 | 2019 | 475 | 0.200 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 211 | 0.200 |
Why?
|
| Self-Help Devices | 1 | 2022 | 12 | 0.200 |
Why?
|
| Pneumococcal Vaccines | 1 | 2024 | 168 | 0.200 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2013 | 43 | 0.200 |
Why?
|
| Caregivers | 3 | 2017 | 578 | 0.200 |
Why?
|
| Transition to Adult Care | 1 | 2024 | 120 | 0.200 |
Why?
|
| Cell Phone | 1 | 2022 | 28 | 0.200 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 292 | 0.200 |
Why?
|
| Skin Tests | 2 | 2019 | 78 | 0.200 |
Why?
|
| Alagille Syndrome | 1 | 2022 | 47 | 0.200 |
Why?
|
| Neutropenia | 2 | 2021 | 200 | 0.200 |
Why?
|
| Pituitary Neoplasms | 1 | 2023 | 84 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 141 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 124 | 0.190 |
Why?
|
| Autoantibodies | 3 | 2024 | 436 | 0.190 |
Why?
|
| Feasibility Studies | 5 | 2025 | 762 | 0.190 |
Why?
|
| Postoperative Complications | 7 | 2021 | 3068 | 0.190 |
Why?
|
| Pediatrics | 3 | 2016 | 1155 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 498 | 0.190 |
Why?
|
| Seizures | 2 | 2017 | 879 | 0.190 |
Why?
|
| Health Literacy | 1 | 2022 | 80 | 0.190 |
Why?
|
| Prognosis | 9 | 2024 | 4607 | 0.180 |
Why?
|
| Disabled Persons | 1 | 2022 | 100 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 662 | 0.180 |
Why?
|
| Educational Measurement | 3 | 2018 | 323 | 0.180 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2022 | 74 | 0.180 |
Why?
|
| Length of Stay | 2 | 2019 | 1309 | 0.180 |
Why?
|
| Pyrazines | 1 | 2021 | 75 | 0.180 |
Why?
|
| HIV Infections | 3 | 2019 | 1896 | 0.180 |
Why?
|
| Self-Management | 2 | 2020 | 98 | 0.180 |
Why?
|
| Checklist | 2 | 2019 | 86 | 0.180 |
Why?
|
| Hypoplastic Left Heart Syndrome | 2 | 2014 | 252 | 0.180 |
Why?
|
| Cholestasis | 1 | 2022 | 154 | 0.180 |
Why?
|
| Insulin Resistance | 2 | 2023 | 645 | 0.180 |
Why?
|
| Aspartate Aminotransferases | 2 | 2023 | 81 | 0.180 |
Why?
|
| Mass Screening | 2 | 2016 | 785 | 0.170 |
Why?
|
| Muscle Strength | 1 | 2021 | 75 | 0.170 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 128 | 0.170 |
Why?
|
| Benzamides | 1 | 2021 | 106 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 504 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 29 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2021 | 206 | 0.170 |
Why?
|
| Risk Factors | 13 | 2023 | 10272 | 0.170 |
Why?
|
| Protons | 2 | 2022 | 91 | 0.170 |
Why?
|
| Liver Glycogen | 1 | 2020 | 23 | 0.170 |
Why?
|
| Lymphoma | 1 | 2023 | 323 | 0.170 |
Why?
|
| Anesthesia, Caudal | 1 | 2020 | 15 | 0.170 |
Why?
|
| Photons | 2 | 2021 | 48 | 0.170 |
Why?
|
| Palliative Care | 2 | 2014 | 429 | 0.170 |
Why?
|
| Adhesins, Bacterial | 1 | 2020 | 75 | 0.170 |
Why?
|
| Severity of Illness Index | 8 | 2023 | 2903 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 96 | 0.170 |
Why?
|
| Cerebellar Neoplasms | 1 | 2023 | 285 | 0.170 |
Why?
|
| House Calls | 1 | 2020 | 37 | 0.170 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 3448 | 0.170 |
Why?
|
| Hydroxyurea | 1 | 2020 | 82 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 2 | 2021 | 523 | 0.170 |
Why?
|
| Salmonella Infections | 1 | 2019 | 31 | 0.160 |
Why?
|
| Knowledge | 1 | 2019 | 47 | 0.160 |
Why?
|
| Brain Edema | 1 | 2020 | 69 | 0.160 |
Why?
|
| Medulloblastoma | 1 | 2023 | 340 | 0.160 |
Why?
|
| Argininosuccinate Lyase | 1 | 2020 | 60 | 0.160 |
Why?
|
| Biofilms | 1 | 2020 | 92 | 0.160 |
Why?
|
| Genes, Bacterial | 1 | 2020 | 209 | 0.160 |
Why?
|
| Computer-Assisted Instruction | 1 | 2019 | 51 | 0.160 |
Why?
|
| Cell Cycle Proteins | 2 | 2023 | 647 | 0.160 |
Why?
|
| Prevalence | 7 | 2024 | 2451 | 0.160 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 224 | 0.160 |
Why?
|
| Models, Educational | 1 | 2019 | 74 | 0.160 |
Why?
|
| Intelligence | 2 | 2019 | 98 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2023 | 807 | 0.160 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 2880 | 0.160 |
Why?
|
| Postpartum Hemorrhage | 1 | 2020 | 96 | 0.160 |
Why?
|
| Disinfection | 2 | 2022 | 26 | 0.160 |
Why?
|
| Anaphylaxis | 2 | 2017 | 80 | 0.160 |
Why?
|
| Polymers | 1 | 2019 | 108 | 0.160 |
Why?
|
| Webcasts as Topic | 1 | 2018 | 6 | 0.160 |
Why?
|
| Mobile Applications | 1 | 2020 | 92 | 0.160 |
Why?
|
| Cross Infection | 1 | 2022 | 329 | 0.160 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1038 | 0.160 |
Why?
|
| Schools | 2 | 2017 | 221 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 203 | 0.160 |
Why?
|
| Videotape Recording | 1 | 2018 | 57 | 0.160 |
Why?
|
| Syphilis, Congenital | 1 | 2019 | 28 | 0.160 |
Why?
|
| Glucose | 1 | 2023 | 885 | 0.160 |
Why?
|
| GABA Modulators | 1 | 2018 | 11 | 0.160 |
Why?
|
| Adenoidectomy | 2 | 2021 | 74 | 0.160 |
Why?
|
| Pentobarbital | 1 | 2018 | 21 | 0.150 |
Why?
|
| Hyperkalemia | 1 | 2019 | 65 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 164 | 0.150 |
Why?
|
| Blood Group Incompatibility | 1 | 2018 | 27 | 0.150 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 429 | 0.150 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 66 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 193 | 0.150 |
Why?
|
| Single-Blind Method | 4 | 2024 | 238 | 0.150 |
Why?
|
| Retina | 1 | 2021 | 453 | 0.150 |
Why?
|
| Furans | 1 | 2018 | 28 | 0.150 |
Why?
|
| Critical Pathways | 1 | 2019 | 77 | 0.150 |
Why?
|
| Airway Management | 1 | 2018 | 66 | 0.150 |
Why?
|
| Syphilis | 1 | 2019 | 96 | 0.150 |
Why?
|
| Ketones | 1 | 2018 | 25 | 0.150 |
Why?
|
| Penicillins | 1 | 2019 | 154 | 0.150 |
Why?
|
| Anilides | 1 | 2018 | 48 | 0.150 |
Why?
|
| Computer Systems | 2 | 2020 | 38 | 0.150 |
Why?
|
| United States | 10 | 2022 | 10886 | 0.150 |
Why?
|
| Fatigue | 2 | 2017 | 194 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2018 | 319 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2021 | 206 | 0.150 |
Why?
|
| Self Care | 2 | 2024 | 214 | 0.150 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 1351 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 140 | 0.150 |
Why?
|
| Prosthesis-Related Infections | 1 | 2020 | 179 | 0.150 |
Why?
|
| Anemia | 1 | 2022 | 340 | 0.150 |
Why?
|
| Hospitalization | 2 | 2024 | 1783 | 0.150 |
Why?
|
| Infant, Newborn | 11 | 2019 | 8182 | 0.140 |
Why?
|
| Patient Handoff | 1 | 2018 | 25 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 538 | 0.140 |
Why?
|
| Intraoperative Care | 1 | 2018 | 104 | 0.140 |
Why?
|
| Insulin | 2 | 2022 | 1210 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 1691 | 0.140 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2017 | 10 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2020 | 305 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2019 | 101 | 0.140 |
Why?
|
| Walk Test | 1 | 2017 | 24 | 0.140 |
Why?
|
| Interpersonal Relations | 2 | 2017 | 229 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2021 | 682 | 0.140 |
Why?
|
| Enterocolitis | 1 | 2017 | 25 | 0.140 |
Why?
|
| Pregnancy | 9 | 2024 | 7172 | 0.140 |
Why?
|
| Vaccination Refusal | 1 | 2017 | 17 | 0.140 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 731 | 0.140 |
Why?
|
| Liver Cirrhosis | 3 | 2023 | 834 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 17 | 0.140 |
Why?
|
| Civil Defense | 1 | 2017 | 8 | 0.140 |
Why?
|
| School Nursing | 1 | 2017 | 8 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2017 | 28 | 0.140 |
Why?
|
| Inflammation | 2 | 2023 | 1428 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 293 | 0.140 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 143 | 0.140 |
Why?
|
| Nurse's Role | 1 | 2017 | 35 | 0.140 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2020 | 205 | 0.140 |
Why?
|
| Anesthetics, Intravenous | 2 | 2014 | 47 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2017 | 41 | 0.140 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2017 | 58 | 0.140 |
Why?
|
| Simian virus 40 | 1 | 2018 | 199 | 0.140 |
Why?
|
| Autistic Disorder | 1 | 2020 | 349 | 0.140 |
Why?
|
| Electrocorticography | 1 | 2017 | 69 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 133 | 0.140 |
Why?
|
| Status Epilepticus | 1 | 2018 | 144 | 0.140 |
Why?
|
| Fathers | 1 | 2017 | 68 | 0.140 |
Why?
|
| Anesthetics, Inhalation | 2 | 2014 | 45 | 0.140 |
Why?
|
| Disaster Planning | 1 | 2017 | 65 | 0.130 |
Why?
|
| Cardiologists | 1 | 2016 | 20 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 70 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 441 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 76 | 0.130 |
Why?
|
| Medical Errors | 1 | 2018 | 155 | 0.130 |
Why?
|
| Immunophenotyping | 1 | 2017 | 330 | 0.130 |
Why?
|
| Phonation | 1 | 2016 | 6 | 0.130 |
Why?
|
| Rituximab | 1 | 2017 | 156 | 0.130 |
Why?
|
| Glioma | 1 | 2021 | 500 | 0.130 |
Why?
|
| Voice Training | 1 | 2016 | 5 | 0.130 |
Why?
|
| Guideline Adherence | 2 | 2018 | 382 | 0.130 |
Why?
|
| Quinolines | 1 | 2017 | 98 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 308 | 0.130 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 349 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 32 | 0.130 |
Why?
|
| Voice Quality | 1 | 2016 | 19 | 0.130 |
Why?
|
| Learning | 1 | 2019 | 363 | 0.130 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 36 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 332 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2018 | 407 | 0.130 |
Why?
|
| Patient Readmission | 2 | 2019 | 383 | 0.130 |
Why?
|
| Decision Making | 2 | 2018 | 654 | 0.130 |
Why?
|
| Intelligence Tests | 1 | 2016 | 57 | 0.130 |
Why?
|
| Air Ambulances | 1 | 2016 | 26 | 0.130 |
Why?
|
| Malawi | 4 | 2019 | 396 | 0.130 |
Why?
|
| Chronic Disease | 4 | 2023 | 1192 | 0.130 |
Why?
|
| Dietary Proteins | 1 | 2017 | 249 | 0.130 |
Why?
|
| Device Removal | 2 | 2017 | 222 | 0.130 |
Why?
|
| Cardiotonic Agents | 1 | 2017 | 138 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2017 | 257 | 0.130 |
Why?
|
| Registries | 6 | 2019 | 1422 | 0.120 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 265 | 0.120 |
Why?
|
| Informed Consent | 1 | 2018 | 336 | 0.120 |
Why?
|
| Emergency Medical Technicians | 1 | 2016 | 45 | 0.120 |
Why?
|
| Shellfish Hypersensitivity | 1 | 2015 | 5 | 0.120 |
Why?
|
| Heart Defects, Congenital | 3 | 2018 | 1813 | 0.120 |
Why?
|
| Fentanyl | 2 | 2013 | 48 | 0.120 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 205 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2018 | 541 | 0.120 |
Why?
|
| Bacteremia | 1 | 2019 | 407 | 0.120 |
Why?
|
| Morphine | 2 | 2013 | 89 | 0.120 |
Why?
|
| School Health Services | 1 | 2016 | 101 | 0.120 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 63 | 0.120 |
Why?
|
| Cardiac Catheterization | 1 | 2019 | 631 | 0.120 |
Why?
|
| Shellfish | 1 | 2015 | 31 | 0.120 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 646 | 0.120 |
Why?
|
| Community Health Services | 1 | 2016 | 90 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 1425 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 76 | 0.120 |
Why?
|
| Basement Membrane | 1 | 2015 | 46 | 0.120 |
Why?
|
| Larynx | 1 | 2016 | 70 | 0.120 |
Why?
|
| Physicians | 2 | 2018 | 582 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 443 | 0.120 |
Why?
|
| Education, Medical, Graduate | 2 | 2024 | 515 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2019 | 554 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2016 | 162 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 283 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 205 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2016 | 228 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 138 | 0.120 |
Why?
|
| Respiration Disorders | 1 | 2014 | 30 | 0.120 |
Why?
|
| Lupus Nephritis | 1 | 2015 | 44 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 58 | 0.120 |
Why?
|
| Social Support | 1 | 2017 | 347 | 0.120 |
Why?
|
| Tracheostomy | 1 | 2017 | 193 | 0.120 |
Why?
|
| Ulna | 1 | 2014 | 6 | 0.110 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2015 | 80 | 0.110 |
Why?
|
| Phenotype | 3 | 2022 | 4261 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1327 | 0.110 |
Why?
|
| Mothers | 1 | 2017 | 354 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 768 | 0.110 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 182 | 0.110 |
Why?
|
| Radius | 1 | 2014 | 25 | 0.110 |
Why?
|
| Wrist Joint | 1 | 2014 | 24 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2014 | 22 | 0.110 |
Why?
|
| Pollen | 1 | 2014 | 46 | 0.110 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 226 | 0.110 |
Why?
|
| Tissue Distribution | 3 | 2019 | 388 | 0.110 |
Why?
|
| Lost to Follow-Up | 1 | 2014 | 32 | 0.110 |
Why?
|
| Renal Dialysis | 3 | 2016 | 855 | 0.110 |
Why?
|
| Logistic Models | 5 | 2017 | 1810 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 240 | 0.110 |
Why?
|
| Aged | 10 | 2023 | 19691 | 0.110 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 7 | 0.110 |
Why?
|
| Hypothermia, Induced | 1 | 2015 | 166 | 0.110 |
Why?
|
| Foreign Bodies | 1 | 2015 | 104 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2014 | 51 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2014 | 66 | 0.110 |
Why?
|
| Baths | 1 | 2013 | 16 | 0.110 |
Why?
|
| Fungi | 1 | 2014 | 69 | 0.110 |
Why?
|
| Reinforcement Schedule | 1 | 2013 | 4 | 0.110 |
Why?
|
| Speech-Language Pathology | 1 | 2013 | 14 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2015 | 194 | 0.110 |
Why?
|
| Hygiene | 1 | 2013 | 25 | 0.110 |
Why?
|
| Chromosome Disorders | 1 | 2016 | 312 | 0.110 |
Why?
|
| Disinfectants | 1 | 2013 | 25 | 0.110 |
Why?
|
| Biliary Atresia | 1 | 2016 | 190 | 0.110 |
Why?
|
| Esophagus | 1 | 2015 | 215 | 0.110 |
Why?
|
| Airway Extubation | 1 | 2014 | 67 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2015 | 224 | 0.110 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 506 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 173 | 0.110 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 27 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 236 | 0.100 |
Why?
|
| Office Visits | 1 | 2013 | 77 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 638 | 0.100 |
Why?
|
| Terminal Care | 1 | 2014 | 112 | 0.100 |
Why?
|
| Reward | 1 | 2013 | 110 | 0.100 |
Why?
|
| Pre-Eclampsia | 1 | 2015 | 221 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2013 | 61 | 0.100 |
Why?
|
| Intensive Care Units, Pediatric | 4 | 2018 | 480 | 0.100 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 116 | 0.100 |
Why?
|
| Head | 1 | 2013 | 103 | 0.100 |
Why?
|
| Incidence | 5 | 2019 | 3144 | 0.100 |
Why?
|
| Sexual Partners | 1 | 2013 | 87 | 0.100 |
Why?
|
| Body Composition | 1 | 2015 | 524 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2015 | 188 | 0.100 |
Why?
|
| Infant Mortality | 1 | 2013 | 173 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 233 | 0.100 |
Why?
|
| Tympanic Membrane | 1 | 2012 | 18 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 154 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2014 | 196 | 0.100 |
Why?
|
| Disease Management | 1 | 2016 | 521 | 0.100 |
Why?
|
| Otologic Surgical Procedures | 1 | 2012 | 23 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 121 | 0.100 |
Why?
|
| Bacteriuria | 1 | 2013 | 82 | 0.100 |
Why?
|
| Abdominal Muscles | 1 | 2012 | 27 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 503 | 0.100 |
Why?
|
| Marfan Syndrome | 1 | 2014 | 139 | 0.100 |
Why?
|
| Genes, Reporter | 1 | 2013 | 383 | 0.100 |
Why?
|
| HIV | 1 | 2013 | 180 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 393 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 723 | 0.100 |
Why?
|
| Otolaryngology | 1 | 2013 | 107 | 0.100 |
Why?
|
| Anesthesia, Local | 1 | 2012 | 48 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 943 | 0.090 |
Why?
|
| Thoracic Surgery | 1 | 2013 | 158 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 332 | 0.090 |
Why?
|
| Analgesics, Opioid | 2 | 2013 | 410 | 0.090 |
Why?
|
| Nerve Fibers | 2 | 2021 | 73 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 632 | 0.090 |
Why?
|
| Cocaine-Related Disorders | 1 | 2013 | 203 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2015 | 401 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 81 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3587 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1604 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 628 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 842 | 0.090 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 277 | 0.090 |
Why?
|
| Premature Birth | 1 | 2015 | 384 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 412 | 0.090 |
Why?
|
| Poverty | 1 | 2014 | 418 | 0.090 |
Why?
|
| Desensitization, Immunologic | 2 | 2022 | 103 | 0.090 |
Why?
|
| Biopsy | 3 | 2023 | 1239 | 0.090 |
Why?
|
| Pneumonia, Viral | 1 | 2016 | 375 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 202 | 0.090 |
Why?
|
| Child Behavior | 1 | 2012 | 230 | 0.090 |
Why?
|
| Heart Failure | 3 | 2018 | 2302 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 638 | 0.080 |
Why?
|
| Survival Rate | 3 | 2020 | 2035 | 0.080 |
Why?
|
| Aorta | 1 | 2013 | 537 | 0.080 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2015 | 506 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 672 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2023 | 4783 | 0.080 |
Why?
|
| Tertiary Care Centers | 3 | 2017 | 236 | 0.080 |
Why?
|
| Immunoglobulin M | 2 | 2024 | 212 | 0.080 |
Why?
|
| von Willebrand Factor | 2 | 2022 | 196 | 0.080 |
Why?
|
| Linear Models | 3 | 2017 | 677 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2014 | 528 | 0.080 |
Why?
|
| Prenatal Diagnosis | 1 | 2013 | 597 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 439 | 0.080 |
Why?
|
| Sleep | 2 | 2022 | 341 | 0.080 |
Why?
|
| Intubation, Intratracheal | 1 | 2012 | 293 | 0.080 |
Why?
|
| Intellectual Disability | 1 | 2016 | 1061 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 1028 | 0.080 |
Why?
|
| United Kingdom | 2 | 2021 | 192 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2015 | 1252 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 1111 | 0.070 |
Why?
|
| Recurrence | 3 | 2017 | 1425 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 143 | 0.070 |
Why?
|
| Kidney | 1 | 2015 | 1354 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2023 | 477 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2019 | 94 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1285 | 0.070 |
Why?
|
| Asymptomatic Diseases | 2 | 2019 | 82 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2013 | 764 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2017 | 3435 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 2142 | 0.070 |
Why?
|
| Immunoglobulin E | 2 | 2019 | 162 | 0.070 |
Why?
|
| Mitochondria | 2 | 2023 | 692 | 0.070 |
Why?
|
| Pain Measurement | 3 | 2013 | 358 | 0.070 |
Why?
|
| Potassium | 2 | 2019 | 280 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 727 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6521 | 0.070 |
Why?
|
| Isotretinoin | 1 | 2006 | 26 | 0.070 |
Why?
|
| Mutagens | 1 | 2006 | 84 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2006 | 58 | 0.060 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 168 | 0.060 |
Why?
|
| Canada | 2 | 2017 | 300 | 0.060 |
Why?
|
| Bleomycin | 1 | 2006 | 150 | 0.060 |
Why?
|
| Disease Progression | 3 | 2019 | 2055 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2013 | 910 | 0.060 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 188 | 0.060 |
Why?
|
| Brain | 1 | 2017 | 3010 | 0.060 |
Why?
|
| Observer Variation | 2 | 2017 | 299 | 0.060 |
Why?
|
| Nuclear Family | 1 | 2005 | 50 | 0.060 |
Why?
|
| Aging | 2 | 2023 | 1189 | 0.060 |
Why?
|
| NEDD8 Protein | 1 | 2024 | 11 | 0.060 |
Why?
|
| Penetrance | 1 | 2005 | 103 | 0.060 |
Why?
|
| Algorithms | 1 | 2011 | 1616 | 0.060 |
Why?
|
| Life Support Care | 1 | 2024 | 46 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 2 | 2017 | 141 | 0.060 |
Why?
|
| Methyl Ethers | 2 | 2014 | 23 | 0.060 |
Why?
|
| C-Peptide | 1 | 2024 | 113 | 0.060 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2024 | 21 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 868 | 0.060 |
Why?
|
| Propofol | 2 | 2014 | 44 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2024 | 180 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 1495 | 0.060 |
Why?
|
| Antigens, CD | 2 | 2018 | 423 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 104 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2006 | 344 | 0.050 |
Why?
|
| Azacitidine | 1 | 2023 | 53 | 0.050 |
Why?
|
| Vidarabine | 1 | 2023 | 80 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1163 | 0.050 |
Why?
|
| Cytarabine | 1 | 2023 | 98 | 0.050 |
Why?
|
| Cell Survival | 2 | 2018 | 807 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2005 | 453 | 0.050 |
Why?
|
| Comorbidity | 2 | 2020 | 1531 | 0.050 |
Why?
|
| Spleen | 1 | 2024 | 282 | 0.050 |
Why?
|
| Reoperation | 2 | 2018 | 833 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2015 | 3287 | 0.050 |
Why?
|
| Endoglin | 1 | 2022 | 22 | 0.050 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 21 | 0.050 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2022 | 24 | 0.050 |
Why?
|
| Pedigree | 2 | 2017 | 1596 | 0.050 |
Why?
|
| Echocardiography | 2 | 2019 | 1052 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 45 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 143 | 0.050 |
Why?
|
| Information Seeking Behavior | 1 | 2022 | 14 | 0.050 |
Why?
|
| Insulin-Secreting Cells | 1 | 2024 | 150 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 776 | 0.050 |
Why?
|
| Emergencies | 1 | 2023 | 173 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 138 | 0.050 |
Why?
|
| Liver | 2 | 2022 | 1764 | 0.050 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1091 | 0.050 |
Why?
|
| Snoring | 1 | 2021 | 16 | 0.050 |
Why?
|
| Blindness | 1 | 2022 | 72 | 0.050 |
Why?
|
| Obstetrics | 1 | 2024 | 237 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2024 | 274 | 0.050 |
Why?
|
| Social Adjustment | 1 | 2022 | 84 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 209 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 3142 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 410 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 1109 | 0.050 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2021 | 36 | 0.050 |
Why?
|
| Glycine Agents | 1 | 2021 | 10 | 0.050 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2021 | 24 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 51 | 0.050 |
Why?
|
| Mice | 4 | 2023 | 17748 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2024 | 259 | 0.050 |
Why?
|
| Fibrosis | 1 | 2023 | 437 | 0.050 |
Why?
|
| Free Radical Scavengers | 1 | 2021 | 49 | 0.050 |
Why?
|
| Resuscitation | 1 | 2023 | 246 | 0.050 |
Why?
|
| Polysomnography | 1 | 2022 | 143 | 0.040 |
Why?
|
| Leukopenia | 1 | 2021 | 44 | 0.040 |
Why?
|
| Body Weight | 2 | 2015 | 1005 | 0.040 |
Why?
|
| Triglycerides | 1 | 2023 | 573 | 0.040 |
Why?
|
| Topotecan | 1 | 2020 | 49 | 0.040 |
Why?
|
| Endothelium | 1 | 2021 | 72 | 0.040 |
Why?
|
| Prenatal Care | 2 | 2014 | 348 | 0.040 |
Why?
|
| Smoking | 1 | 2006 | 1044 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 2021 | 106 | 0.040 |
Why?
|
| Animals | 5 | 2023 | 34186 | 0.040 |
Why?
|
| Biological Availability | 1 | 2020 | 135 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2022 | 172 | 0.040 |
Why?
|
| Palpation | 1 | 2020 | 18 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 8 | 0.040 |
Why?
|
| Genotype | 1 | 2006 | 2557 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 22 | 0.040 |
Why?
|
| Monosaccharides | 1 | 2020 | 23 | 0.040 |
Why?
|
| Needles | 1 | 2020 | 51 | 0.040 |
Why?
|
| Phthalazines | 1 | 2019 | 13 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 174 | 0.040 |
Why?
|
| Triticum | 1 | 2019 | 34 | 0.040 |
Why?
|
| Fermentation | 1 | 2020 | 66 | 0.040 |
Why?
|
| Eggs | 1 | 2019 | 24 | 0.040 |
Why?
|
| Vincristine | 1 | 2020 | 195 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 40 | 0.040 |
Why?
|
| Oligosaccharides | 1 | 2020 | 73 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 155 | 0.040 |
Why?
|
| Internet | 1 | 2022 | 383 | 0.040 |
Why?
|
| Survivors | 1 | 2022 | 339 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 392 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 239 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 198 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2022 | 409 | 0.040 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 85 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 297 | 0.040 |
Why?
|
| New Orleans | 1 | 2019 | 13 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 13 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 227 | 0.040 |
Why?
|
| Milk | 1 | 2019 | 119 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 342 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 1899 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2018 | 66 | 0.040 |
Why?
|
| Achievement | 1 | 2018 | 31 | 0.040 |
Why?
|
| Sarcoma | 1 | 2021 | 194 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 485 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 421 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 275 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 466 | 0.040 |
Why?
|
| Patient Simulation | 1 | 2018 | 39 | 0.040 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2018 | 16 | 0.040 |
Why?
|
| Goals | 1 | 2019 | 128 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 54 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1017 | 0.040 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2018 | 88 | 0.040 |
Why?
|
| Specialization | 1 | 2018 | 75 | 0.040 |
Why?
|
| Orthopedics | 1 | 2018 | 66 | 0.040 |
Why?
|
| Cell Transformation, Viral | 1 | 2018 | 106 | 0.040 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2017 | 6 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2017 | 26 | 0.040 |
Why?
|
| Manikins | 1 | 2018 | 135 | 0.040 |
Why?
|
| DNA Damage | 1 | 2021 | 515 | 0.040 |
Why?
|
| Pregnancy, High-Risk | 1 | 2017 | 43 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2018 | 101 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 88 | 0.040 |
Why?
|
| Microtubules | 1 | 2018 | 197 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2018 | 236 | 0.030 |
Why?
|
| Hydrocephalus | 1 | 2020 | 244 | 0.030 |
Why?
|
| Heart Rate | 1 | 2020 | 594 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 26 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2018 | 167 | 0.030 |
Why?
|
| Skin | 1 | 2020 | 512 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1108 | 0.030 |
Why?
|
| Social Workers | 1 | 2017 | 6 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 4356 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 141 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 68 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 168 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 38 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 130 | 0.030 |
Why?
|
| Epinephrine | 1 | 2018 | 178 | 0.030 |
Why?
|
| Epilepsies, Partial | 1 | 2017 | 93 | 0.030 |
Why?
|
| Exome | 1 | 2022 | 1042 | 0.030 |
Why?
|
| Family | 1 | 2020 | 565 | 0.030 |
Why?
|
| Vomiting | 1 | 2017 | 107 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 117 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1105 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 75 | 0.030 |
Why?
|
| Emergency Medicine | 1 | 2018 | 155 | 0.030 |
Why?
|
| Sound Spectrography | 1 | 2016 | 7 | 0.030 |
Why?
|
| Stroboscopy | 1 | 2016 | 4 | 0.030 |
Why?
|
| Neurology | 1 | 2018 | 108 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 301 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 652 | 0.030 |
Why?
|
| Legionella | 1 | 2016 | 9 | 0.030 |
Why?
|
| Acoustics | 1 | 2016 | 20 | 0.030 |
Why?
|
| Pneumocystis carinii | 1 | 2016 | 9 | 0.030 |
Why?
|
| Comprehension | 1 | 2017 | 75 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2018 | 257 | 0.030 |
Why?
|
| Medicaid | 1 | 2019 | 243 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 230 | 0.030 |
Why?
|
| Pregnant Women | 1 | 2017 | 146 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 400 | 0.030 |
Why?
|
| Chickenpox Vaccine | 1 | 2016 | 13 | 0.030 |
Why?
|
| General Surgery | 1 | 2018 | 204 | 0.030 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 14 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 2016 | 30 | 0.030 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 13 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 327 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 690 | 0.030 |
Why?
|
| Potassium Radioisotopes | 1 | 2015 | 6 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 86 | 0.030 |
Why?
|
| Hepatitis B Vaccines | 1 | 2016 | 41 | 0.030 |
Why?
|
| Lymphadenitis | 1 | 2015 | 26 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 51 | 0.030 |
Why?
|
| Wasting Syndrome | 1 | 2015 | 25 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 254 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 316 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2015 | 51 | 0.030 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 35 | 0.030 |
Why?
|
| Apgar Score | 1 | 2015 | 47 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2015 | 16 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 136 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 28 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 243 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 757 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2016 | 147 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 43 | 0.030 |
Why?
|
| Failure to Thrive | 1 | 2015 | 90 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2015 | 99 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 301 | 0.030 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2016 | 79 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2016 | 160 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 398 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2015 | 146 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 415 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 275 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 244 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 803 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2017 | 481 | 0.030 |
Why?
|
| Perinatal Death | 1 | 2015 | 26 | 0.030 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2015 | 57 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 565 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 530 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 354 | 0.030 |
Why?
|
| Education, Medical | 1 | 2018 | 287 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2015 | 69 | 0.030 |
Why?
|
| Oligohydramnios | 1 | 2015 | 46 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 390 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 496 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2015 | 193 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 590 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 82 | 0.030 |
Why?
|
| Aftercare | 1 | 2015 | 148 | 0.030 |
Why?
|
| Surgeons | 1 | 2018 | 255 | 0.030 |
Why?
|
| Elastic Tissue | 1 | 2013 | 19 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2013 | 33 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 35 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 444 | 0.030 |
Why?
|
| Elastin | 1 | 2013 | 31 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 547 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 686 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 374 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 404 | 0.030 |
Why?
|
| Isoflurane | 1 | 2013 | 42 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2013 | 86 | 0.030 |
Why?
|
| Birth Weight | 1 | 2015 | 348 | 0.030 |
Why?
|
| Substance Abuse Detection | 1 | 2013 | 41 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1247 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1027 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 40 | 0.030 |
Why?
|
| Asymptomatic Infections | 1 | 2013 | 34 | 0.030 |
Why?
|
| Echoencephalography | 1 | 2013 | 25 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2013 | 88 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 532 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1228 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2013 | 43 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2013 | 62 | 0.030 |
Why?
|
| Hospitals, County | 1 | 2013 | 23 | 0.030 |
Why?
|
| Fluorescence | 1 | 2013 | 95 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 824 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2018 | 494 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 240 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 376 | 0.030 |
Why?
|
| Biosensing Techniques | 1 | 2013 | 53 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 334 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 1136 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 647 | 0.030 |
Why?
|
| Social Participation | 1 | 2012 | 20 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2013 | 97 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2771 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2013 | 160 | 0.030 |
Why?
|
| Social Stigma | 1 | 2013 | 74 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2014 | 216 | 0.030 |
Why?
|
| Infant Behavior | 1 | 2012 | 14 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 585 | 0.030 |
Why?
|
| Body Image | 1 | 2012 | 38 | 0.030 |
Why?
|
| Anesthesia Recovery Period | 1 | 2012 | 23 | 0.020 |
Why?
|
| Chest Tubes | 1 | 2012 | 36 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 1587 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2012 | 19 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 478 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2044 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 777 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 778 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 325 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 443 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2012 | 135 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 255 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2012 | 55 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3061 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 196 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 240 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 828 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2015 | 387 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 973 | 0.020 |
Why?
|
| Delirium | 1 | 2012 | 54 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 294 | 0.020 |
Why?
|
| Self Concept | 1 | 2012 | 160 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 385 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2017 | 658 | 0.020 |
Why?
|
| Nerve Block | 1 | 2012 | 65 | 0.020 |
Why?
|
| Gestational Age | 1 | 2015 | 1161 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 222 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2013 | 351 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2305 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 374 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 492 | 0.020 |
Why?
|
| Emotions | 1 | 2012 | 364 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1600 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 1568 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 523 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 954 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 607 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1265 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1636 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2014 | 774 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4430 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2014 | 810 | 0.020 |
Why?
|
| Lod Score | 1 | 2005 | 120 | 0.010 |
Why?
|
| Chromosome Segregation | 1 | 2005 | 63 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 5812 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 759 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 821 | 0.010 |
Why?
|